Previous 10 | Next 10 |
Timber Pharmaceuticals press release ( NYSE: TMBR ): Q3 GAAP EPS of -$1.52. Timber ended the third quarter with approximately $11.2 million in cash and 2.7 million shares of common stock outstanding after giving retroactive effect to a 1-for-50 reverse split of its shares ...
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal Phase 3 ASCEND clinical trial continues to progress; expected to enroll more than 140 patients with moderate to severe Congenital Ichthyosis- BASKING RIDGE...
BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare ...
Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split BASKING RIDGE, NJ - ( NewMediaWire ) - November 3, 2022 - Timber Pharmaceutic...
Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special Meeting of Stockholders on November 7, 2022 and Consummation of Reverse Stock Split BASKING RIDGE, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timbe...
The European Commission (EC) granted orphan designation to Timber Pharmaceuticals' ( NYSE: TMBR ) TMB-001 to treat autosomal recessive congenital ichthyosis (ARCI). Ichthyosis is a condition which causes persistent thick and dry skin. The European Medicines Ag...
- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application - - Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the Treatment of X-Linked Recessive Ichthyosis - BASKING...
Timber Pharmaceuticals' ( NYSE: TMBR ) stock fell ~21% on Oct. 3 after the company said that it signed an agreement with institutional investors to raise $1.3M from a registered direct offering. The company is selling 13M common shares, and Series 1 commo...
BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treat...
Timber Pharma ( NYSE: TMBR ) is trading 8.8% higher after it sa id on Wednesday the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) issued a positive opinion on its application for orphan designation for drug, TMB-001, to treat autos...
News, Short Squeeze, Breakout and More Instantly...
Timber Pharmaceuticals Inc. Company Name:
TMBR Stock Symbol:
NYSE Market:
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that...
WARREN, NJ - ( NewMediaWire ) - November 28, 2023 - Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-...
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated d...